| P50 | author | Svetlana Donina | Q90213430 |
| | Galina Petukhova | Q105046068 |
| | Daniil Korenkov | Q42115794 |
| | Larisa Rudenko | Q42115804 |
| | Irina Isakova-Sivak | Q54696429 |
| | Marina Stukova | Q54696433 |
| P2093 | author name string | Jorge Flores | |
| | Anatoly Naykhin | |
| | Alexandra Nikiforova | |
| | Igor Losev | |
| | Mariana Erofeeva | |
| | Maureen Power | |
| P2860 | cites work | H5N1 vaccines in humans | Q27000896 |
| | Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus | Q30205252 |
| | Development of live attenuated influenza vaccines against pandemic influenza strains | Q30209998 |
| | Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries. | Q30226518 |
| | [Comparative clinical trial of vaccines against avian influenza] | Q80728024 |
| | DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials | Q85047234 |
| | Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine. | Q30359013 |
| | A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response. | Q30359896 |
| | Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine. | Q30369136 |
| | Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. | Q30371327 |
| | H2N2 live attenuated influenza vaccine is safe and immunogenic for healthy adult volunteers. | Q30373298 |
| | Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study. | Q30378200 |
| | Influence of prior influenza vaccination on antibody and B-cell responses | Q33361605 |
| | Validation of the ALS assay in adult patients with culture confirmed pulmonary tuberculosis | Q33808888 |
| | Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. | Q33974507 |
| | Distinct cross-reactive B-cell responses to live attenuated and inactivated influenza vaccines | Q34354440 |
| | Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children | Q35167127 |
| | Avidity of immunoglobulin G directed against human cytomegalovirus during primary and secondary infections in immunocompetent and immunocompromised subjects | Q35230133 |
| | Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. | Q35634295 |
| | Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. | Q36237991 |
| | Localized mucosal response to intranasal live attenuated influenza vaccine in adults | Q36606611 |
| | Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect | Q36974932 |
| | Memory T-cell immune response in healthy young adults vaccinated with live attenuated influenza A (H5N2) vaccine. | Q38627438 |
| | Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines | Q39320852 |
| | Development of a novel in vitro assay (ALS assay) for evaluation of vaccine-induced antibody secretion from circulating mucosal lymphocytes | Q39508187 |
| | Plasmablast-derived polyclonal antibody response after influenza vaccination | Q40339871 |
| | Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. | Q43208959 |
| | Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population | Q44363590 |
| | Comparative immunogenicity and cross-clade protective efficacy of mammalian cell-grown inactivated and live attenuated H5N1 reassortant vaccines in ferrets | Q44943273 |
| | Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against supralethal challenge with heterosubtypic virus | Q45408591 |
| | Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. | Q46325181 |
| | Comparative studies of local antibody and cellular immune responses to influenza infection and vaccination with live attenuated reassortant influenza vaccine (LAIV) utilizing a mouse nasal-associated lymphoid tissue (NALT) separation method | Q47841089 |
| | [Stimulation of homo- and heterologic T-cell immunological memory in volunteers inoculated with live influenza A (H5N2) reassortant vaccine]. | Q50953448 |
| | Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. | Q51777217 |
| | Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents | Q74128278 |
| P433 | issue | 12 | |
| P921 | main subject | influenza vaccine | Q383260 |
| | attenuated vaccine | Q1810913 |
| P304 | page(s) | 2839-2848 | |
| P577 | publication date | 2015-12-01 | |
| P1433 | published in | Human Vaccines & Immunotherapeutics | Q21072749 |
| P1476 | title | Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine. | |
| P478 | volume | 11 | |